查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1383600

後天孤兒血液疾病治療市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按治療、疾病適應症、配銷通路、地區和競爭細分

Acquired Orphan Blood Diseases Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Therapy, By Disease Indication, By Distribution Channel, by region, and Competition
出版日期: | 出版商: TechSci Research | 英文 178 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022 年，全球獲得性孤兒血液疾病治療市場價值為 79.5 億美元，預計在預測期內將出現令人印象深刻的成長，到 2028 年複合CAGR為7.80%。獲得性孤兒血液疾病是一個涵蓋一組罕見和罕見疾病的術語。通常會危及生命的疾病會影響血液及其成分（例如紅血球、白血球、血小板），並且不是遺傳的，而是在人的一生中獲得的。這些血液疾病並非出生時就存在，也不是透過遺傳遺傳的。相反，它們通常是由於各種觸發因素或潛在的健康狀況而在人的一生中形成或獲得的。獲得性孤兒血液疾病的診斷、治療和管理通常需要血液科醫生或其他在罕見血液疾病方面具有專業知識的醫療保健提供者的專門護理。治療方法可能包括輸血、免疫抑制治療、標靶治療，在某些情況下還包括骨髓移植。

包括基因組學、免疫學和分子生物學在內的醫學研究的不斷進步加深了我們對這些疾病發病機制的了解。這些知識支持標靶療法和治療創新的開發。孤兒藥指定提供的監管激勵措施，例如擴大市場獨佔權、稅收抵免和降低開發成本，鼓勵製藥公司投資於罕見疾病的研發。患者權益團體和組織在推動研究、提高意識和倡導改善治療機會方面發揮關鍵作用。他們的努力有助於加速獲得性孤兒血液疾病領域的進展。包括基因療法、單株抗體和免疫調節劑在內的新型治療方式的出現，擴大了後天性孤兒血液疾病的治療選擇範圍。診斷技術和技術的進步使得獲得性孤兒血液疾病的診斷更加準確和及時。這使得早期干預和治療成為可能。

主要市場促進因素

市場概況
預測期 2024-2028
2022 年市場規模 79.5億美元
2028 年市場規模 125.7億美元
2023-2028 年CAGR 7.80%
成長最快的細分市場 醫院藥房
最大的市場 北美洲

醫學研究的進展

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球獲得性孤兒血液疾病治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依治療（重組因子、免疫球蛋白輸注療法、活化凝血酶原複合物濃縮物、血小板生成素受體激動劑、其他）
    • 依疾病適應症（後天性粒細胞缺乏症、後天性血友病、後天性血管性血友病症候群、陣發性睡眠性血紅素尿症 (PNH)、骨髓增生異常症候群等）
    • 按配銷通路（醫院藥房、零售藥房、其他）
    • 按公司分類 (2022)
  • 市場地圖

第 6 章：亞太地區後天性孤兒血液疾病治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 透過治療
    • 按疾病適應症
    • 按配銷通路
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國獲得孤兒血液疾病治療藥物
    • 印度獲得性孤兒血液疾病治療
    • 澳洲獲得性孤兒血液疾病治療
    • 日本獲得性孤兒血液疾病療法
    • 韓國獲得孤兒血液疾病治療藥物

第 7 章：歐洲後天孤兒血液疾病治療市場前景

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 透過治療
    • 按疾病適應症
    • 按配銷通路
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 8 章：北美後天性孤兒血液疾病治療市場前景

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 透過治療
    • 按疾病適應症
    • 按配銷通路
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 9 章：南美洲後天孤兒血液疾病治療市場前景

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 透過治療
    • 按疾病適應症
    • 按配銷通路
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲後天孤兒血液疾病治療市場前景

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 透過治療
    • 按疾病適應症
    • 按配銷通路
    • 按國家/地區
  • MEA：國家分析
    • 南非後天孤兒血液疾病治療
    • 沙烏地阿拉伯獲得孤兒血液疾病治療藥物
    • 阿拉伯聯合大公國獲得性孤兒血液疾病治療

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 13 章：全球獲得性孤兒血液疾病治療市場：SWOT 分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第 15 章：大環境分析

第16章：競爭格局

  • 亞力兄製藥公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 安進公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 新基公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 禮來公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 賽諾菲公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 葛蘭素史克公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • Cyclacel 製藥公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • Onconova 治療公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 因塞特公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • CTI生物製藥公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis

第 17 章：策略建議

第 18 章：關於我們與免責聲明

簡介目錄
Product Code: 18730

Global Acquired Orphan Blood Diseases Therapeutics Market has valued at USD 7.95 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 7.80% through 2028. Acquired orphan blood diseases is a term that encompasses a group of rare and often life-threatening medical conditions that affect the blood and its components (e.g., red blood cells, white blood cells, platelets) and are not inherited but acquired during a person's lifetime. These blood diseases are not present at birth or inherited through genetics. Instead, they develop or are acquired during a person's life, often due to various triggers or underlying health conditions. Diagnosis, treatment, and management of acquired orphan blood diseases often require specialized care from hematologists or other healthcare providers with expertise in rare blood disorders. Treatment approaches may include blood transfusions, immunosuppressive therapies, targeted therapies, and, in some cases, bone marrow transplantation.

Ongoing advancements in medical research, including genomics, immunology, and molecular biology, have deepened our understanding of the pathogenesis of these diseases. This knowledge supports the development of targeted therapies and treatment innovations. Regulatory incentives provided by orphan drug designations, such as extended market exclusivity, tax credits, and reduced development costs, encourage pharmaceutical companies to invest in research and development for rare diseases. Patient advocacy groups and organizations play a pivotal role in driving research, raising awareness, and advocating for improved access to treatments. Their efforts help accelerate progress in the field of acquired orphan blood diseases. The emergence of novel treatment modalities, including gene therapies, monoclonal antibodies, and immunomodulatory agents, has expanded the range of therapeutic options available for acquired orphan blood diseases. Advances in diagnostic techniques and technologies have led to more accurate and timely diagnoses of acquired orphan blood diseases. This enables early intervention and treatment.

Key Market Drivers

Market Overview
Forecast Period2024-2028
Market Size 2022USD 7.95 Billion
Market Size 2028USD 12.57 Billion
CAGR 2023-20287.80%
Fastest Growing SegmentHospital Pharmacy
Largest MarketNorth America

Advancements in Medical Research

Medical research has deepened our understanding of the underlying mechanisms and pathophysiology of acquired orphan blood diseases. This knowledge helps identify novel therapeutic targets and pathways for intervention. Research efforts have led to the development of targeted therapies that address the specific molecular and cellular abnormalities associated with these diseases. Targeted treatments often offer better efficacy and safety profiles compared to traditional therapies. Research has contributed to the identification of biomarkers and genetic markers associated with these diseases. Biomarkers enable early diagnosis, disease monitoring, and personalized treatment approaches. Ongoing research supports drug discovery and development programs aimed at creating innovative and more effective therapeutics. This includes the development of monoclonal antibodies, gene therapies, and small molecule drugs. Advances in clinical trial design and methodology, including adaptive trials and innovative endpoints, facilitate the evaluation of potential therapies. Clinical trials are essential for assessing treatment safety and efficacy. Medical research has led to the creation of patient registries and databases for rare diseases. These registries facilitate data collection, epidemiological studies, and clinical trial recruitment.

Collaborative efforts among researchers and healthcare institutions on a global scale promote knowledge sharing and accelerate research progress. These collaborations can lead to the discovery of novel therapies. Research has advanced the concept of precision medicine, allowing for tailored treatment approaches based on individual patient characteristics, including genetics and biomarkers. The development of disease models, such as in vitro cell cultures and animal models, enables researchers to test potential therapies and gain insights into disease mechanisms. Research findings are disseminated through scientific publications and conferences, raising awareness among healthcare providers, patients, and pharmaceutical companies about potential therapeutic options. Medical research actively involves patients in clinical trials and research initiatives. Patient engagement helps ensure that treatments meet the needs and preferences of those affected by these rare diseases. Advances in research often inform regulatory agencies' understanding of rare diseases and their willingness to provide expedited pathways for orphan drug designations and approvals. This factor will help in the development of the Global Acquired Orphan Blood Diseases Therapeutics Market.

Emerging Therapies

Emerging therapies often represent innovative and groundbreaking approaches to treating acquired orphan blood diseases. These therapies may include gene therapies, monoclonal antibodies, cell-based therapies, and small molecule drugs designed to target specific disease mechanisms. Many emerging therapies are designed to be more effective than traditional treatments. They may offer improved disease management, symptom control, and overall outcomes for patients, which makes them highly desirable in the medical community. Some emerging therapies have the potential to modify the course of the disease, halt its progression, or even provide a cure. This transformative impact on patients' lives drives significant demand. Many emerging therapies are designed to be more targeted, which can lead to fewer side effects and a better safety profile compared to older treatments. This can improve patient compliance and overall quality of life. Emerging therapies often take a patient-centric approach, tailoring treatments to individual patients based on their genetic and molecular characteristics. This personalized medicine approach is highly appealing to both patients and healthcare providers. Regulatory agencies may expedite the approval process for emerging therapies, recognizing their potential to address unmet medical needs in rare diseases. This accelerates their availability in the market.

The introduction of novel therapies can expand the overall market for acquired orphan blood disease therapeutics as more healthcare providers and patients seek these cutting-edge treatments. The promise of emerging therapies attracts increased investment from pharmaceutical companies and biotechnology firms. This investment drives research and development efforts in the field. Patients and advocacy groups often advocate for access to emerging therapies that can offer better outcomes and quality of life. Their advocacy contributes to the demand for these treatments. As emerging therapies demonstrate their effectiveness, healthcare providers are more likely to adopt them into their treatment protocols, further driving demand. Emerging therapies can lead to better disease management and reduced complications, resulting in cost savings for healthcare systems in the long run. The presence of emerging therapies in the market fosters competition among pharmaceutical companies. This competition can lead to price considerations and potentially more accessible treatment options. This factor will pace up the demand of the Global Acquired Orphan Blood Diseases Therapeutics Market.

Rising Demand of Orphan Drug Designations

Orphan drug designations provide pharmaceutical companies with various incentives, such as extended market exclusivity, tax credits, and research grants. These incentives make it more attractive for companies to invest in the research and development of treatments for rare diseases, including acquired orphan blood diseases. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), often offer expedited review and approval processes for orphan drugs. This accelerates the development timeline, allowing promising therapies to reach the market more quickly. Orphan drug designations typically grant a period of market exclusivity during which competing treatments cannot enter the market for the same indication. This exclusivity provides a competitive advantage and encourages pharmaceutical companies to pursue orphan drug development. Tax credits and reduced regulatory fees for orphan drugs can significantly lower the overall cost of drug development. This financial support makes it more financially viable for companies to invest in rare disease therapeutics.

Regulatory incentives often lead to quicker approvals and reduced regulatory burdens, facilitating easier market access for orphan drugs. Healthcare providers and patients can access these therapies sooner, increasing demand. Orphan drug designations attract increased research efforts into acquired orphan blood diseases. This expanded research not only helps identify potential therapies but also raises awareness about these rare conditions. Patient advocacy groups and organizations dedicated to rare diseases actively promote the benefits of orphan drug designations. They advocate for increased funding, research, and access to orphan drugs, contributing to demand. The availability of orphan drugs encourages healthcare providers to improve diagnostic capabilities, leading to earlier and more accurate diagnoses of acquired orphan blood diseases. Timely diagnosis drives the demand for effective therapies. Regulatory agencies worldwide have implemented orphan drug programs and designations, leading to greater international collaboration in rare disease research and development. This harmonization streamlines the path to market for orphan drugs. As more orphan drugs receive designations and approvals, the market for acquired orphan blood disease therapeutics expands. The availability of multiple treatment options contributes to market growth. The prospect of orphan drug designations attracts increased investment from both pharmaceutical companies and venture capitalists. This influx of funding accelerates research and development efforts. Effective orphan drugs can significantly enhance the quality of life for patients with acquired orphan blood diseases. This improvement in patient outcomes drives demand for these treatments. This factor will accelerate the demand of the Global Acquired Orphan Blood Diseases Therapeutics Market.

Key Market Challenges

Access to Treatment

Rare diseases, including acquired orphan blood diseases, often have a limited number of treatment options available due to their low prevalence. This scarcity of therapies can make it difficult for patients to access appropriate treatments. Many orphan drugs and emerging therapies are associated with high treatment costs. The rarity of these diseases and the costs of research and development often result in expensive therapies, making them financially burdensome for patients and healthcare systems. Acquired orphan blood diseases are not always well-known among healthcare providers and the public. This lack of awareness can lead to delayed diagnoses and difficulty in accessing specialized treatments. Access to advanced medical treatments can vary significantly based on geographic location. Patients in remote or underserved areas may face challenges in accessing specialized healthcare facilities and therapies. In some regions, the healthcare infrastructure may not be adequately equipped to diagnose and manage acquired orphan blood diseases. This can lead to delays in treatment initiation. The availability and extent of insurance coverage for orphan blood disease therapies can vary widely. In some cases, insurance plans may not fully cover the cost of treatment, leaving patients with high out-of-pocket expenses. Pharmaceutical companies may encounter challenges in obtaining reimbursement approvals for orphan drugs, leading to delays in patients' access to treatment. Specialized treatment centers and healthcare providers with expertise in acquired orphan blood diseases may be concentrated in urban areas, making it challenging for patients in rural regions to access care.

Economic and Pricing Pressures

Developing treatments for acquired orphan blood diseases can be exceptionally costly due to the limited patient population, complex research requirements, and the need for specialized therapies. These high development costs can put pressure on pharmaceutical companies to recoup their investments through pricing. The small number of patients with acquired orphan blood diseases means that pharmaceutical companies have a smaller market to target. To make their treatments financially viable, they may need to set higher prices per patient. Pricing for orphan drugs is often scrutinized for transparency, and the public and healthcare providers may question the justification for high drug prices, particularly when the cost-benefit ratio is unclear. Patients and healthcare providers may face challenges in obtaining insurance coverage for expensive orphan drugs. Insurers may hesitate to cover these therapies due to their high cost, leaving patients with significant out-of-pocket expenses. High drug prices can create barriers to access for patients who cannot afford the cost of treatment, potentially limiting their ability to benefit from lifesaving or life-improving therapies. Healthcare systems and payers often have budget constraints, and the introduction of costly orphan drugs can strain healthcare budgets. This can lead to challenges in negotiating pricing agreements with pharmaceutical companies. Economic disparities within and between countries can affect patients' access to orphan drugs. Patients in wealthier regions or countries may have better access, while those in poor areas may struggle to obtain treatment.

Key Market Trends

Expanded Access Programs

(Expanded access programs) EAPs prioritize the needs of patients who have limited or no alternative treatment options. These programs provide access to potentially life-saving therapies, reflecting a patient-centered approach to healthcare. EAPs allow patients to access investigational or emerging therapies that are still in the clinical trial or regulatory approval phases. This can be especially valuable for patients with rare and life-threatening diseases like acquired orphan blood diseases. EAPs are driven by ethical considerations, recognizing the urgency of providing treatments to patients who may not qualify for clinical trials or cannot wait for regulatory approvals. They provide hope and potential benefits to those in need. Patients who do not respond to standard therapies or who have contraindications to traditional treatments may find EAPs as a viable option for accessing novel treatments tailored to their specific condition. EAPs allow for the collection of real-world data and evidence regarding the safety and efficacy of therapies in diverse patient populations. This information can complement clinical trial data and inform treatment decisions. EAPs involve close collaboration between physicians, patients, pharmaceutical companies, and regulatory authorities. This collaboration ensures that patients receive the most appropriate and personalized care.

Segmental Insights

Therapy Insights

In 2022, the Global Acquired Orphan Blood Diseases Therapeutics Market largest share was held by Immunoglobulin Infusion Therapy segment and is predicted to continue expanding over the coming years. Immunoglobulin infusion therapy is a versatile treatment option used for a wide range of acquired orphan blood diseases, including immune thrombocytopenia (ITP), acquired hemophilia, and paroxysmal nocturnal hemoglobinuria (PNH), among others. This broad application makes it a common therapeutic choice for multiple conditions. Immunoglobulin therapy works by modulating the immune system, which is often a key factor in the pathogenesis of acquired orphan blood diseases. It can help regulate autoantibody production and reduce the immune response against self-components, providing a treatment option for autoimmune-based blood disorders. Some acquired orphan blood diseases, such as acquired hemophilia and severe ITP, can lead to life-threatening bleeding episodes. Immunoglobulin infusion therapy can be administered as an emergency treatment to control bleeding, making it a critical option in such situations.

Disease Indication Insights

In 2022, the Global Acquired Orphan Blood Diseases Therapeutics Market largest share was held by Acquired Hemophilia segment and is predicted to continue expanding over the coming years. Acquired hemophilia is a rare and potentially life-threatening bleeding disorder characterized by the development of autoantibodies against clotting factors, particularly factor VIII. While it is a rare condition, its incidence is relatively higher compared to some other acquired orphan blood diseases, which may contribute to its larger share of the market. Acquired hemophilia can present with severe and spontaneous bleeding episodes, which can be life-threatening. This clinical severity necessitates prompt diagnosis and treatment, leading to a higher demand for therapeutics. Advances in diagnostic methods and increased awareness of acquired hemophilia have led to earlier and more accurate diagnoses. This, in turn, has driven the demand for therapeutic interventions. The treatment of acquired hemophilia can be complex and may require a combination of therapies, including factor replacement, immunosuppressive drugs, and supportive care. These multiple treatment modalities contribute to a larger market share.

Distribution Channel Insights

In 2022, the Global Acquired Orphan Blood Diseases Therapeutics Market largest share was held by Hospital Pharmacy segment in the forecast period and is predicted to continue expanding over the coming years. Hospitals often have specialized departments and centers dedicated to the treatment of rare and complex diseases, including acquired orphan blood diseases. These centers have the expertise, equipment, and infrastructure to diagnose, manage, and treat these conditions effectively. Hospitals typically employ a multidisciplinary team of healthcare professionals, including hematologists, oncologists, pharmacists, and nurses, who are experienced in managing acquired orphan blood diseases. This expertise is critical for diagnosing and providing comprehensive care to patients. Hospitals often serve as primary sites for conducting clinical trials and research studies on orphan blood disease therapeutics. Clinical trials are essential for evaluating the safety and efficacy of new treatments, and hospitals have the resources to facilitate these trials. Acquired orphan blood diseases, especially those associated with bleeding or thrombosis, may require emergency care and interventions. Hospitals are equipped to provide immediate medical attention and critical care when needed.

Regional Insights

The North America region dominates the Global Acquired Orphan Blood Diseases Therapeutics Market in 2022. North America, particularly the United States, is a global hub for pharmaceutical and biotechnology research and development. Many leading pharmaceutical companies and research institutions in the region focus on rare diseases, including acquired orphan blood diseases. This concentration of expertise and resources drives innovation and the development of new therapies. The United States has well-established regulatory agencies, such as the U.S. Food and Drug Administration (FDA), that have implemented orphan drug designations and fast-track approval processes for rare disease therapies. These regulatory incentives have encouraged pharmaceutical companies to invest in orphan disease research and development. The North American market, including the United States and Canada, is substantial in terms of both population and healthcare spending. This creates a sizable market for orphan disease therapeutics, attracting investments and driving market growth. North America boasts advanced healthcare infrastructure and facilities, which enable the diagnosis and treatment of rare diseases, including acquired orphan blood diseases. Access to specialized medical centers and expertise is crucial for patients with these conditions.

Key Market Players

Alexion Pharmaceuticals, Inc.

Amgen, Inc.

Celgene Corporation

Eli Lilly and Company

Sanofi S.A.

GlaxoSmithKline plc,

Cyclacel Pharmaceuticals, Inc.

Onconova Therapeutics, Inc.

Incyte Corporation,

CTI BioPharma Corp

Report Scope:

In this report, the Global Acquired Orphan Blood Diseases Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Acquired Orphan Blood Diseases Therapeutics Market, By Therapy:

  • Recombinant Factor
  • Immunoglobulin Infusion Therapy
  • Activated Prothrombin Complex Concentrate
  • Thrombopoietin Receptor Agonists
  • Others

Acquired Orphan Blood Diseases Therapeutics Market, By Disease Indication:

  • Acquired Agranulocytosis
  • Acquired Hemophilia
  • Acquired Von Willebrand Syndrome
  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • Myelodysplastic Syndrome
  • Others

Acquired Orphan Blood Diseases Therapeutics Market, By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

Global Acquired Orphan Blood Diseases Therapeutics Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Acquired Orphan Blood Diseases Therapeutics Market.

Available Customizations:

  • Global Acquired Orphan Blood Diseases Therapeutics Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Acquired Orphan Blood Diseases Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapy (Recombinant Factor, Immunoglobulin Infusion Therapy, Activated Prothrombin Complex Concentrate, Thrombopoietin Receptor Agonists, Others)
    • 5.2.2. By Disease Indication (Acquired Agranulocytosis, Acquired Hemophilia, Acquired Von Willebrand Syndrome, Paroxysmal Nocturnal Hemoglobinuria (PNH), Myelodysplastic Syndrome, Others)
    • 5.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others)
    • 5.2.4. By Company (2022)
  • 5.3. Market Map

6. Asia Pacific Acquired Orphan Blood Diseases Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapy
    • 6.2.2. By Disease Indication
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Acquired Orphan Blood Diseases Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapy
        • 6.3.1.2.2. By Disease Indication
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. India Acquired Orphan Blood Diseases Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapy
        • 6.3.2.2.2. By Disease Indication
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Australia Acquired Orphan Blood Diseases Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapy
        • 6.3.3.2.2. By Disease Indication
        • 6.3.3.2.3. By Distribution Channel
    • 6.3.4. Japan Acquired Orphan Blood Diseases Therapeutics Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Therapy
        • 6.3.4.2.2. By Disease Indication
        • 6.3.4.2.3. By Distribution Channel
    • 6.3.5. South Korea Acquired Orphan Blood Diseases Therapeutics Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Therapy
        • 6.3.5.2.2. By Disease Indication
        • 6.3.5.2.3. By Distribution Channel

7. Europe Acquired Orphan Blood Diseases Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy
    • 7.2.2. By Disease Indication
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Acquired Orphan Blood Diseases Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapy
        • 7.3.1.2.2. By Disease Indication
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. Germany Acquired Orphan Blood Diseases Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapy
        • 7.3.2.2.2. By Disease Indication
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. Spain Acquired Orphan Blood Diseases Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapy
        • 7.3.3.2.2. By Disease Indication
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Acquired Orphan Blood Diseases Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Therapy
        • 7.3.4.2.2. By Disease Indication
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. United Kingdom Acquired Orphan Blood Diseases Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Therapy
        • 7.3.5.2.2. By Disease Indication
        • 7.3.5.2.3. By Distribution Channel

8. North America Acquired Orphan Blood Diseases Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy
    • 8.2.2. By Disease Indication
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Acquired Orphan Blood Diseases Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapy
        • 8.3.1.2.2. By Disease Indication
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. Mexico Acquired Orphan Blood Diseases Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapy
        • 8.3.2.2.2. By Disease Indication
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Canada Acquired Orphan Blood Diseases Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapy
        • 8.3.3.2.2. By Disease Indication
        • 8.3.3.2.3. By Distribution Channel

9. South America Acquired Orphan Blood Diseases Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy
    • 9.2.2. By Disease Indication
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Acquired Orphan Blood Diseases Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapy
        • 9.3.1.2.2. By Disease Indication
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Argentina Acquired Orphan Blood Diseases Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapy
        • 9.3.2.2.2. By Disease Indication
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. Colombia Acquired Orphan Blood Diseases Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapy
        • 9.3.3.2.2. By Disease Indication
        • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Acquired Orphan Blood Diseases Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapy
    • 10.2.2. By Disease Indication
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Acquired Orphan Blood Diseases Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapy
        • 10.3.1.2.2. By Disease Indication
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Saudi Arabia Acquired Orphan Blood Diseases Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapy
        • 10.3.2.2.2. By Disease Indication
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. UAE Acquired Orphan Blood Diseases Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapy
        • 10.3.3.2.2. By Disease Indication
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Acquired Orphan Blood Diseases Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

  • 16.1. Alexion Pharmaceuticals, Inc.
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (In case of listed companies)
    • 16.1.5. Recent Developments
    • 16.1.6. SWOT Analysis
  • 16.2. Amgen, Inc.
    • 16.2.1. Business Overview
    • 16.2.2. Company Snapshot
    • 16.2.3. Products & Services
    • 16.2.4. Financials (In case of listed companies)
    • 16.2.5. Recent Developments
    • 16.2.6. SWOT Analysis
  • 16.3. Celgene Corporation
    • 16.3.1. Business Overview
    • 16.3.2. Company Snapshot
    • 16.3.3. Products & Services
    • 16.3.4. Financials (In case of listed companies)
    • 16.3.5. Recent Developments
    • 16.3.6. SWOT Analysis
  • 16.4. Eli Lilly and Company
    • 16.4.1. Business Overview
    • 16.4.2. Company Snapshot
    • 16.4.3. Products & Services
    • 16.4.4. Financials (In case of listed companies)
    • 16.4.5. Recent Developments
    • 16.4.6. SWOT Analysis
  • 16.5. Sanofi SA
    • 16.5.1. Business Overview
    • 16.5.2. Company Snapshot
    • 16.5.3. Products & Services
    • 16.5.4. Financials (In case of listed companies)
    • 16.5.5. Recent Developments
    • 16.5.6. SWOT Analysis
  • 16.6. GlaxoSmithKline plc
    • 16.6.1. Business Overview
    • 16.6.2. Company Snapshot
    • 16.6.3. Products & Services
    • 16.6.4. Financials (In case of listed companies)
    • 16.6.5. Recent Developments
    • 16.6.6. SWOT Analysis
  • 16.7. Cyclacel Pharmaceuticals Inc.
    • 16.7.1. Business Overview
    • 16.7.2. Company Snapshot
    • 16.7.3. Products & Services
    • 16.7.4. Financials (In case of listed companies)
    • 16.7.5. Recent Developments
    • 16.7.6. SWOT Analysis
  • 16.8. Onconova Therapeutics, Inc
    • 16.8.1. Business Overview
    • 16.8.2. Company Snapshot
    • 16.8.3. Products & Services
    • 16.8.4. Financials (In case of listed companies)
    • 16.8.5. Recent Developments
    • 16.8.6. SWOT Analysis
  • 16.9. Incyte Corporation
    • 16.9.1. Business Overview
    • 16.9.2. Company Snapshot
    • 16.9.3. Products & Services
    • 16.9.4. Financials (In case of listed companies)
    • 16.9.5. Recent Developments
    • 16.9.6. SWOT Analysis
  • 16.10. CTI BioPharma Corp
    • 16.10.1. Business Overview
    • 16.10.2. Company Snapshot
    • 16.10.3. Products & Services
    • 16.10.4. Financials (In case of listed companies)
    • 16.10.5. Recent Developments
    • 16.10.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer